filmov
tv
Highlights on IDH1 and 2 inhibitors
Показать описание
AML Hub
Рекомендации по теме
0:02:06
Highlights on IDH1 and 2 inhibitors
0:02:46
The rapid progression of IDH1/2 mutant enzyme inhibitors through clinical trials
0:01:53
Treatment strategies for patients with IDH1/2-mutated AML ineligible for intensive chemotherapy
0:05:47
IDH1/2 Inhibitors for AML
0:01:48
IDH1 inhibitor ivosidenib for the treatment of relapsed/ refractory AML
0:01:25
IDH inhibitors for AML: highlights from ASH 2018
0:37:51
Implications of Rapid IDH1/IDH2 Testing for Liquid and Solid Tumors
0:02:22
Session highlights: IDH inhibitors, salvage regimens, and other novel developments in AML
0:01:14
The impact of IDH mutations in MDS & evaluating the role of IDH inhibitors
0:03:23
The prognostic value of IDH1 and IDH2 in acute myeloid leukemia (AML)
0:01:03
IDH mutations in AML
0:03:57
The efficacy of FLT3 and IDH1/2 inhibitors in patients with AML previously treated with venetoclax
0:01:11
Are IDH mutations good minimal residual disease (MRD) markers in acute myeloid leukemia (AML)?
0:04:21
Positive Results With Ivosidenib in IDH1-Mutated AML
0:02:21
The future of AML treatment? Progress in IDH1/2 inhibitors for AML
0:01:32
IDH inhibitors for AML and MDS
0:02:26
What are the latest updates on the IDH1 and IDH2 inhibitor studies?
0:03:49
Clinical challenges with new and emerging IDH1/IDH2 inhibito
0:03:08
AML highlights from ASH 2017
0:01:59
IDH inhibitors
0:01:06
INDIGO: clinical benefit of vorasidenib in patients with grade 2 IDH-mutant glioma
0:03:55
Genomic updates in the field of MPNs
0:06:29
Accelerated Magnetic Resonance Spectroscopic Imaging Acquisition for Renal Cell Carcinoma
0:04:19
Molecular characterization of patients in AGILE: azacitidine + ivosidenib or placebo in IDH1m AML
visit shbcf.ru
0:02:06
0:02:46
0:01:53
0:05:47
0:01:48
0:01:25
0:37:51
0:02:22
0:01:14
0:03:23
0:01:03
0:03:57
0:01:11
0:04:21
0:02:21
0:01:32
0:02:26
0:03:49
0:03:08
0:01:59
0:01:06
0:03:55
0:06:29
0:04:19